Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Reprinted from over a year ago..

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
XenaLives Member Profile
Member Level 
Followed By 318
Posts 40,995
Boards Moderated 30
Alias Born 09/20/01
160x600 placeholder
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 2/20/2020 4:32:14 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:38:56 PM
PURA ALERT - MACD Cross Pushing $0.039 50 Day MA With $0.35 Analyst TGT Recommendation InvestorsHub NewsWire - 2/10/2020 12:50:46 PM
PURA BUY Recommendation at $0.03 Issued By AmericanBulls InvestorsHub NewsWire - 2/7/2020 10:33:33 AM
Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates GlobeNewswire Inc. - 2/6/2020 7:00:10 AM
Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference GlobeNewswire Inc. - 2/4/2020 7:00:10 AM
Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Developmen... GlobeNewswire Inc. - 2/3/2020 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020 GlobeNewswire Inc. - 1/30/2020 7:00:10 AM
Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Dis... GlobeNewswire Inc. - 1/27/2020 7:00:10 AM
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 6:00:00 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
XenaLives Member Level  Saturday, 04/20/19 08:43:53 PM
Re: georgejjl post# 190079
Post # of 237889 
Reprinted from over a year ago..

Quote:

My point is that there is no "normal" process in the EU at this time. Where did you get your 2% figure? The fact is that if 2-73 is a significant improvement over L-dopa for Parkinson's it will go through the regulatory process in an expedited manner.

Dr. Angela Cenci-Nilsson was Dr. Veronica Francardo's PHD sponsor.
Quote:

"L-dopa…waiting for the next act" with Dr. Angela Cenci-Nilsson
Published on Published onFebruary 8, 2016
Elizabeth (Eli) Pollard

Executive Director at World Parkinson Coalition
19 articles

Why has it taken over 50 years to improve the delivery systems of L-dopa and what can people with Parkinson's expect in the near future? Dr. Angela Cenci-Nilsson of Lund University and who sits on the WPC 2016 Steering Committee, is this month's special guest on the Portland Countdown podcast program. She talks about "L-dopa … waiting for the next act" with Jon Palfreman and Dave Iverson.
I often hear people talk about how ridiculous it is that l-dopa is still the golden drug of choice for addressing Parkinson's symptoms. People want more treatment options, but those who use l-dopa and get good results, could't live without this "old" drug. Isn't it possible to have researchers keep fine tuning the drugs on the market, while others keep searching for new treatments? Dave says in the podcast that refining drugs is not sexy or that lucrative for pharma, but he and Jon agree that refining some of these old drugs, like levodopa is crucial to improving the lives of PwP.
Should people with Parkinson's become more involved in the research process and move from advocates to activists in order to influence funding decisions? PD activists might have more success influencing researchers and companies to do some of the research they may not be that eager to take on, such as the refining of drugs already on the market.
I often hear that PwP are too nice, and that if they want to get more done, they need to take a page out of the AIDS activists' book and get more aggressive in order to push for more changes in treatment options or to refine the drugs that are already on the market.
Is now the time to get more aggressive? If you could dictate PD research right now, starting immediately, what would you ask researchers to focus on?



https://www.linkedin.com/pulse/l-dopawaiting-next-act-dr-angela-cenci-nilsson-pollard/

Original post:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137969688



In Peace, In War
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist